Navigation Links
LA BioMed researcher says 'unexpected' increase in cancer risk found
Date:3/4/2008

TORRANCE An increased cancer risk in post-menopausal women after they stopped taking combined hormone therapy was an unexpected finding in a study that will be reported in the March 5 edition of the Journal of the American Medical Association (JAMA), said Rowan T. Chlebowski, M.D., Ph.D., a Los Angeles Biomedical Research Institute (LA BioMed) lead investigator who contributed to the study.

This latest study reinforces the original finding that combined hormone therapy of estrogen plus progestin should not be taken for the purpose of reducing disease in post-menopausal women, Chlebowski said. These findings also reinforce the need for monitoring for cancer in women who have taken the combination of estrogen plus progestin.

Dr. Chlebowski is a medical oncologist who has led several prior reports focusing on hormone effects on malignancies, including breast and colorectal cancer. He was a member of the team of researchers, led by Gerardo Heiss, M.D., of the University of North Carolina, Chapel Hill, N.C., who authored the March 5 JAMA report on a follow-up study of post-menopausal women enrolled in the Womens Health Initiative. Dr. Chlebowski is available for comment for reporters seeking further insight into the studys findings.

About the Womens Health Initiative

The Womens Health Initiative (WHI) trial began in 1993 to measure the effect of estrogen plus progestin on reducing disease in post-menopausal women. It included 16,608 postmenopausal women and assessed whether conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) prevents heart disease and hip fractures and increases the risk of breast cancer.

The trial was stopped in 2002 when data indicated an increased risk of breast cancer and a failure to demonstrate an overall health benefit of the therapy. Further analysis showed that women taking the two hormones had higher risks of cardiovascular disease, coronary heart disease, stroke and venous thromboembolism and lower risks of fracture and colorectal cancer.

About the Follow-Up Study

After stopping intervention, WHI followed the trial participants using the same study protocol of semi-annual monitoring to identify and classify study outcomes, in order to evaluate the effects of stopping hormone therapy.

Post intervention information for the period July 8, 2002 to March 31, 2005 was available on 95% of the women. The JAMA article reports on health outcomes at three years after the intervention was stopped (mean of 2.4 years of follow-up).

In the three years after stopping hormone therapy women who previously used estrogen plus progestin no longer had an increased risk of cardiovascular disease (heart disease, stroke, and blood clots) compared with women on placebo.

The lower risk of colorectal cancer and fractures seen during the trial in women who previously used estrogen plus progestin disappeared after stopping the combined hormone therapy.

But the risk of all cancers combined in women who previously used estrogen plus progestin increased after stopping the intervention compared to those previously on placebo. This was due to increases in a variety of cancers, including lung cancer.

After stopping the hormone therapy, mortality from all causes was somewhat higher in women who previously used estrogen plus progestin compared with those taking a placebo.


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
2. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
3. Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science
4. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
5. Lung Cancer Alliance Urges Inclusion of $5 Billion for Biomedical Research in Economic Stimulus Package
6. BioMed Central bolsters radiology image collection
7. New nanotube findings by Stanford researchers give boost to potential biomedical applications
8. American Red Cross Announces New Leader for Biomedical Services
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
11. LA BioMed researchers find few emergency rooms fully equipped for pediatric patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: